Cargando…
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Subsets of patients with non-small cell lung cancer respond remarkably well to small molecule tyrosine kinase inhibitors (TKI) specific for epidermal growth factor receptor (EGFR) such as gefitinib or erlotinib. In 2004, it was found that EGFR mutations occurring in the kinase domain are strongly as...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360106/ https://www.ncbi.nlm.nih.gov/pubmed/17325698 http://dx.doi.org/10.1038/sj.bjc.6603665 |